Pediatric Hematologist Oncologist and BMT Flowship Non-Communicable Pediatrics Diseases Research Center, Babol University of Medical Sciences, Babol, Iran.


The thalassamias refer to a diverse group of hemoglobin disorders characterized by a reduced synthesis of  one or more of globin chains (α,β, γ, δβ,γδβ, δ and εγδβ).The main cure available today for thalassamia is bone marrow transplantation (BMT)  from compatible donor.On December 3, 1981 a 14-month-old child with β-thalassemia major recieved BMT from his HLA-identical sister in Seattle.On December 17, 1981 the Pesaro team performed a transplant in a 16-year old thalassamia, using marrow from his HLA-identical brother.This patient rejected the graft.
In our study, twenty twotransfusion dependentthalassemia patients were recruited.When HLA matched donor was detected, he or she was checked for asymptomatic infection, electerolytes and endocrinopathy. Donors were either heterozygous for β-thalassemia or normal homozygous.
In our center 22 transfusion dependent hemglobinopathies (10 girls and 12 boys,age3-26y, Mean=15.6y) underwent to HSCT from September 2010 until May  2014.Graft failure happened in 3 patients. Retransplantation was done for one patient who was X variant hemoglobinopathy.Twenty patients were disease free and didn`t need to transfusion after BMT. Although in our BMT center , few thalassemia patients underwent to transplantation, 20 of 22 were independent to blood transfusion after transplantation. One patient who underwent to retransplantation is undependent to transfusion.
Patients and their family were very pleasured and satisfied. We suggest all patients with β-thalassemia who have HLA-identical related donors should be transplanted as soon as possible.
Keyword: Bone Marrow Transplant, HLA-identical, β-thalassemia.